Citizens Reiterates Market Outperform on Mirum Pharmaceuticals, Maintains $137 Price Target

Mirum Pharmaceuticals

Mirum Pharmaceuticals

MIRM

0.00

Citizens analyst Jonathan Wolleben reiterates Mirum Pharmaceuticals (NASDAQ: MIRM) with a Market Outperform and maintains $137 price target.